Almost every corner of the broader healthcare sector has been on a tear since October. Among the all industries, Pharmaceuticals gained the most in October itself, adding 8.7%. Pharma was followed by Biotechnology (up 6.9%), Health Care Services (up 3.8%) and Healthcare Equipment (up 1.1%).
Inside the Rally
Per the Earnings Trends issued on Nov 6, 2019, total earnings of 91.6% of the entire healthcare market capitalization that has reported so far are up 7.0% on revenue growth of 7.8%. The earnings growth rate seems to be the fifth highest among the 16 Zacks classified sectors. Revenue growth rate was the third-highest. Blended beat ratio was 69.6%, which was the third highest.
Medical – Drugs belongs to a top-ranked Zacks industry (top 23%). Shares of the industry can be availed at 17.53x forward earnings or less against the S&P 500 ETF IVV’s P/E multiple of 19.04x. Though low P/E does not indicate future stock performance, cheaper valuation is always lucrative amid a spate of good news. The projected ESP growth rate of the sector was 9.49% versus 5.68% of IVV. Debt-to-equity ratio of the industry (0.2x) is much lower than that of 0.72x.
Large Cap Pharmaceuticals also belongs to a top-ranked Zacks industry (top 36%). The industry has a forward P/E ratio of 14.63x, which ensures its undervalued status. Debt-to-equity ratio of the industry (0.71x) is in line with that of the S&P 500.
There was positive news in the industry. Biogen (BIIB - Free Report) spread optimism into the broad healthcare sector following its Alzheimer’s treatment report. The biotech company decided to go ahead with the approval of aducanumab, a treatment for early Alzheimer’s diseases, after the drug met the primary endpoint of a Phase 3 Emerge study (read: Healthcare ETFs Win in October: Here's Why).
Hepion Pharmaceuticals also led the sector higher following data that showed potential for its CRV431 as a drug candidate for liver disease treatment. Alexion Pharmaceuticals (ALXN - Free Report) agreed to acquire a clinical-stage biopharmaceutical company Achillion Pharmaceuticals (ACHN - Free Report) . All these positive developments fueled the rally in the pharma and biotech sectors in October.
Below we highlight top-performing ETFs and stocks from the sector in the past four-week period (as of Nov 6, 2019) (see all Health Care ETFs here).
GlycoMimetics Inc. (GLYC - Free Report) – Up 31.6%; Zacks Rank #2 (Buy)
Rigel Pharmaceuticals Inc. (RIGL - Free Report) – Up 31.1%; Zacks Rank #2
Ironwood Pharmaceuticals Inc. (IRWD - Free Report) ) – Up 28.3%; Zacks Rank #1(Strong Buy)
Dermira Inc. (DERM - Free Report) ) – Up 23.5%; Zacks Rank #1
SPDR S&P Pharmaceuticals ETF (XPH - Free Report) – Up 9.6%; Zacks Rank #3 (Hold)
Invesco Dynamic Pharmaceuticals ETF (PJP - Free Report) – Up 6.3%; Zacks Rank #3
VanEck Vectors Pharmaceutical ETF (PPH - Free Report) – Up 6.1%; Zacks Rank #3
First Trust Nasdaq Pharmaceuticals ETF (FTXH) – Up 5.2%; Zacks Rank #3
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>